Advanced search
Publication Cover
OncoTargets and Therapy Volume 16, 2023 - Issue
Submit an article Journal homepage
244
Views
2
CrossRef citations to date
0
Altmetric
CASE REPORT

Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report

Junmei Shi1 Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
,
Zhaohui Jia2 Clinical Pharmacology, The First Affiliated Hospital of Xingtai Medical College, Xingtai, People’s Republic of China
,
Zhiguo Zhou1 Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
,
Liyan Zhao2 Clinical Pharmacology, The First Affiliated Hospital of Xingtai Medical College, Xingtai, People’s Republic of China
,
Qingju Meng2 Clinical Pharmacology, The First Affiliated Hospital of Xingtai Medical College, Xingtai, People’s Republic of ChinaCorrespondence[email protected]
&
Yibing Liu1 Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaCorrespondence[email protected]
Pages 109-114 | Received 06 Sep 2022, Accepted 07 Feb 2023, Published online: 17 Feb 2023

References

  • Stockhammer P, Ho CSL, Hegedus L, et al. HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. Lung Cancer. 2020;144:20–29. doi:10.1016/j.lungcan.2020.04.002
  • Liu C, Yu H, Long Q, et al. Real world experience of crizotinib in 104 patients with ALK rearrangement non-small-cell lung cancer in a single Chinese Cancer Center. Front Oncol. 2019;9:1116. doi:10.3389/fonc.2019.01116
  • Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019;14(7):1233–1243. doi:10.1016/j.jtho.2019.03.007
  • Sushi Yatabe Y. ALK FISH and IHC: cannot have one without the other. JTO. 2021;10(4):548–550.
  • Feng T, Chen Z, Gu J, et al. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma. Lung Cancer. 2019;137:19–22. doi:10.1016/j.lungcan.2019.08.032
  • Guo L, Cui C, Wang J, et al. PINCH-1 regulates mitochondrial dynamics to promote proline synthesis and tumor growth. Nat Commun. 2020;11(1):4913. doi:10.1038/s41467-020-18753-6
  • Hee PC, Young RS, Bae AJ, et al. PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. Int J Cancer. 2015;136(10):2273–2283. doi:10.1002/ijc.29273
  • Qian T, Liu C, Ding Y, et al. PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis. Oncogene. 2020;39(10):2069–2087. doi:10.1038/s41388-019-1135-5
  • Benjamin J, Tony M, Dong-Wan K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177. doi:10.1056/NEJMoa1408440
  • Sai-Hong I, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-Positive NSCLC. Ann Oncol. 2014;25:415–422. doi:10.1093/annonc/mdt572
  • Zhang M, Wang Q, Ding Y, et al. CUX1-ALK, a novel ALK rearrangement that responds to crizotinib in non-small cell lung cancer. J Thorac Oncol. 2018;13(11):1792–1797. doi:10.1016/j.jtho.2018.07.008
  • Sun K, Nie L, Nong L, Cheng Y. Primary resistance to alectinib in a patient with STRN-ALK -positive non-small cell lung cancer: a case report. Thorac Cancer. 2021;12(12):1927–1930. doi:10.1111/1759-7714.13983
  • Frost N, Christopoulos P, Kauffmann-Guerrero D, et al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 2021;13:175883592098055. doi:10.1177/1758835920980558

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.